Novocure Revenue and Competitors




Total Funding

Estimated Revenue & Valuation

  • Novocure's estimated annual revenue is currently $545.8M per year.(i)
  • Novocure received $150.0M in venture funding in February 2018.
  • Novocure's estimated revenue per employee is $322,559
  • Novocure's total funding is $875M.
  • Novocure's current valuation is $7.4B. (January 2022)

Employee Data

  • Novocure has 1692 Employees.(i)
  • Novocure grew their employee count by 9% last year.

Novocure's People

FounderReveal Email/Phone
CEOReveal Email/Phone
VP, Business DevelopmentReveal Email/Phone
Head EngineeringReveal Email/Phone
SVP, Enterprise Transformation and Global Revenue OperationsReveal Email/Phone
Head Global ProcurementReveal Email/Phone
VP IT Infrastructure and CybersecurityReveal Email/Phone
Head Talent & DevelopmentReveal Email/Phone
VP, Head Government AffairsReveal Email/Phone
VP, Thoracic Business UnitReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Novocure?

We are a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. We count on the contributions of our talented team members who are committed to improving the lives of cancer patients. Here at Novocure, cancer patients and their families are and have always been at the core of our mission. We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. We offer employment opportunities in the U.S., Europe and Asia.

keywords:Biotechnology,Hardware,Healthcare,Medical Devices,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Novocure News

2022-04-20 - Seagen and NovoCure to Open New Manufacturing and ...

NovoCure is headquartered on the coast opposite Seagen, in New Jersey. Thus far, the company has expanded into Tokyo, Israel, and Root,...

2022-04-20 - NovoCure (NVCR) to Release Quarterly Earnings on Thursday

The medical equipment provider reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.15). NovoCure had a...

2022-04-19 - Novocure Hosts Ceremonial Groundbreaking with New ...

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and...

2021-02-25 - Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

ST. HELIER, Jersey--(BUSINESS WIRE)--Feb 25, 2021-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical and product development pro ...

2015-01-08 - Novocure Enteres into $100M Term Loan Agreement with Pharmakon Advisors

Novocure, a commercial stage oncology company, entered into a term loan agreement with an investment fund managed by Pharmakon Advisors LP. The agreement provides Novocure with up to $100m of available borrowing capacity. Under the terms of the agreement, Pharmakon will provide $25m at closing ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Novocure Funding

DateAmountRoundLead InvestorsReference
2015-01-09$100.0MUndisclosedPharmakon Advisors LPArticle
2018-02-08$150.0MUndisclosedBioPharma Credit PLCArticle